Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt No Debt
DRAD's Cash to Debt is ranked higher than
96% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. DRAD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
DRAD' s 10-Year Cash to Debt Range
Min: 0.56  Med: 9999.00 Max: No Debt
Current: No Debt
Equity to Asset 0.79
DRAD's Equity to Asset is ranked higher than
72% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. DRAD: 0.79 )
Ranked among companies with meaningful Equity to Asset only.
DRAD' s 10-Year Equity to Asset Range
Min: -1.99  Med: 0.81 Max: 0.84
Current: 0.79
-1.99
0.84
Interest Coverage 64.56
DRAD's Interest Coverage is ranked lower than
63% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. DRAD: 64.56 )
Ranked among companies with meaningful Interest Coverage only.
DRAD' s 10-Year Interest Coverage Range
Min: 0.66  Med: 10000.00 Max: 9999.99
Current: 64.56
0.66
9999.99
F-Score: 7
Z-Score: 3.88
M-Score: -2.66
WACC vs ROIC
8.42%
27.86%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 5.03
DRAD's Operating margin (%) is ranked higher than
55% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.12 vs. DRAD: 5.03 )
Ranked among companies with meaningful Operating margin (%) only.
DRAD' s 10-Year Operating margin (%) Range
Min: -182.88  Med: -9.49 Max: 4.53
Current: 5.03
-182.88
4.53
Net-margin (%) 5.97
DRAD's Net-margin (%) is ranked higher than
62% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.45 vs. DRAD: 5.97 )
Ranked among companies with meaningful Net-margin (%) only.
DRAD' s 10-Year Net-margin (%) Range
Min: -190.47  Med: -8.54 Max: 4.45
Current: 5.97
-190.47
4.45
ROE (%) 10.18
DRAD's ROE (%) is ranked higher than
72% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. DRAD: 10.18 )
Ranked among companies with meaningful ROE (%) only.
DRAD' s 10-Year ROE (%) Range
Min: -14.95  Med: -9.36 Max: 7.5
Current: 10.18
-14.95
7.5
ROA (%) 8.01
DRAD's ROA (%) is ranked higher than
79% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: -0.62 vs. DRAD: 8.01 )
Ranked among companies with meaningful ROA (%) only.
DRAD' s 10-Year ROA (%) Range
Min: -172.76  Med: -7.64 Max: 5.94
Current: 8.01
-172.76
5.94
ROC (Joel Greenblatt) (%) 35.20
DRAD's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. DRAD: 35.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
DRAD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -134.97  Med: -30.05 Max: 34.95
Current: 35.2
-134.97
34.95
Revenue Growth (3Y)(%) 1.50
DRAD's Revenue Growth (3Y)(%) is ranked lower than
58% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. DRAD: 1.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DRAD' s 10-Year Revenue Growth (3Y)(%) Range
Min: -90.7  Med: -6.70 Max: 35.4
Current: 1.5
-90.7
35.4
» DRAD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

DRAD Guru Trades in Q2 2014

Jim Simons 889,030 sh (+5.24%)
» More
Q3 2014

DRAD Guru Trades in Q3 2014

Jim Simons 1,007,133 sh (New)
Jim Simons 931,630 sh (+4.79%)
» More
Q4 2014

DRAD Guru Trades in Q4 2014

Jim Simons 1,007,133 sh (+8.10%)
» More
Q1 2015

DRAD Guru Trades in Q1 2015

Jim Simons 926,200 sh (-8.04%)
» More
» Details

Insider Trades

Latest Guru Trades with DRAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 25.47
DRAD's P/E(ttm) is ranked higher than
57% of the 155 Companies
in the Global Medical Devices industry.

( Industry Median: 28.20 vs. DRAD: 25.47 )
Ranked among companies with meaningful P/E(ttm) only.
DRAD' s 10-Year P/E(ttm) Range
Min: 15.36  Med: 31.93 Max: 202.11
Current: 25.47
15.36
202.11
PE(NRI) 25.90
DRAD's PE(NRI) is ranked higher than
56% of the 153 Companies
in the Global Medical Devices industry.

( Industry Median: 28.20 vs. DRAD: 25.90 )
Ranked among companies with meaningful PE(NRI) only.
DRAD' s 10-Year PE(NRI) Range
Min: 15.29  Med: 31.92 Max: 192
Current: 25.9
15.29
192
P/B 2.38
DRAD's P/B is ranked higher than
63% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 3.23 vs. DRAD: 2.38 )
Ranked among companies with meaningful P/B only.
DRAD' s 10-Year P/B Range
Min: 0.19  Med: 1.19 Max: 2.87
Current: 2.38
0.19
2.87
P/S 1.48
DRAD's P/S is ranked higher than
72% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.28 vs. DRAD: 1.48 )
Ranked among companies with meaningful P/S only.
DRAD' s 10-Year P/S Range
Min: 0.02  Med: 0.86 Max: 1.99
Current: 1.48
0.02
1.99
PFCF 15.58
DRAD's PFCF is ranked higher than
83% of the 114 Companies
in the Global Medical Devices industry.

( Industry Median: 32.21 vs. DRAD: 15.58 )
Ranked among companies with meaningful PFCF only.
DRAD' s 10-Year PFCF Range
Min: 0.13  Med: 16.98 Max: 353
Current: 15.58
0.13
353
POCF 13.21
DRAD's POCF is ranked higher than
80% of the 148 Companies
in the Global Medical Devices industry.

( Industry Median: 21.95 vs. DRAD: 13.21 )
Ranked among companies with meaningful POCF only.
DRAD' s 10-Year POCF Range
Min: 0.08  Med: 17.46 Max: 412
Current: 13.21
0.08
412
EV-to-EBIT 22.06
DRAD's EV-to-EBIT is ranked higher than
50% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 22.01 vs. DRAD: 22.06 )
Ranked among companies with meaningful EV-to-EBIT only.
DRAD' s 10-Year EV-to-EBIT Range
Min: -128.3  Med: -2.40 Max: 293.9
Current: 22.06
-128.3
293.9
Current Ratio 3.86
DRAD's Current Ratio is ranked higher than
65% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. DRAD: 3.86 )
Ranked among companies with meaningful Current Ratio only.
DRAD' s 10-Year Current Ratio Range
Min: 1.03  Med: 4.62 Max: 5.53
Current: 3.86
1.03
5.53
Quick Ratio 3.43
DRAD's Quick Ratio is ranked higher than
68% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. DRAD: 3.43 )
Ranked among companies with meaningful Quick Ratio only.
DRAD' s 10-Year Quick Ratio Range
Min: 0.88  Med: 4.13 Max: 4.82
Current: 3.43
0.88
4.82
Days Inventory 33.35
DRAD's Days Inventory is ranked higher than
92% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 129.39 vs. DRAD: 33.35 )
Ranked among companies with meaningful Days Inventory only.
DRAD' s 10-Year Days Inventory Range
Min: 31.58  Med: 42.06 Max: 54.41
Current: 33.35
31.58
54.41
Days Sales Outstanding 45.65
DRAD's Days Sales Outstanding is ranked higher than
81% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 68.45 vs. DRAD: 45.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
DRAD' s 10-Year Days Sales Outstanding Range
Min: 38.23  Med: 42.92 Max: 79.15
Current: 45.65
38.23
79.15

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.59
DRAD's Dividend Yield is ranked higher than
93% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 1.43 vs. DRAD: 4.59 )
Ranked among companies with meaningful Dividend Yield only.
DRAD' s 10-Year Dividend Yield Range
Min: 1.3  Med: 4.43 Max: 5.45
Current: 4.59
1.3
5.45
Dividend Payout 1.13
DRAD's Dividend Payout is ranked lower than
97% of the 108 Companies
in the Global Medical Devices industry.

( Industry Median: 0.41 vs. DRAD: 1.13 )
Ranked among companies with meaningful Dividend Payout only.
DRAD' s 10-Year Dividend Payout Range
Min: 1  Med: 1.25 Max: 1.28
Current: 1.13
1
1.28
Yield on cost (5-Year) 4.67
DRAD's Yield on cost (5-Year) is ranked higher than
87% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 1.37 vs. DRAD: 4.67 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
DRAD' s 10-Year Yield on cost (5-Year) Range
Min: 1.3  Med: 4.43 Max: 5.45
Current: 4.67
1.3
5.45
Share Buyback Rate 0.30
DRAD's Share Buyback Rate is ranked higher than
83% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. DRAD: 0.30 )
Ranked among companies with meaningful Share Buyback Rate only.
DRAD' s 10-Year Share Buyback Rate Range
Min: 0.3  Med: -0.95 Max: -1314
Current: 0.3

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.25
DRAD's Price/Net Cash is ranked higher than
74% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 14.31 vs. DRAD: 7.25 )
Ranked among companies with meaningful Price/Net Cash only.
DRAD' s 10-Year Price/Net Cash Range
Min: 0.68  Med: 2.59 Max: 7.69
Current: 7.25
0.68
7.69
Price/Net Current Asset Value 3.51
DRAD's Price/Net Current Asset Value is ranked higher than
78% of the 205 Companies
in the Global Medical Devices industry.

( Industry Median: 6.76 vs. DRAD: 3.51 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
DRAD' s 10-Year Price/Net Current Asset Value Range
Min: 0.33  Med: 1.66 Max: 3.72
Current: 3.51
0.33
3.72
Price/Tangible Book 2.83
DRAD's Price/Tangible Book is ranked higher than
65% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 4.56 vs. DRAD: 2.83 )
Ranked among companies with meaningful Price/Tangible Book only.
DRAD' s 10-Year Price/Tangible Book Range
Min: 0.23  Med: 1.27 Max: 3.01
Current: 2.83
0.23
3.01
Price/Projected FCF 2.19
DRAD's Price/Projected FCF is ranked lower than
54% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. DRAD: 2.19 )
Ranked among companies with meaningful Price/Projected FCF only.
DRAD' s 10-Year Price/Projected FCF Range
Min: 1.1  Med: 2.06 Max: 2.93
Current: 2.19
1.1
2.93
Price/Median PS Value 1.68
DRAD's Price/Median PS Value is ranked lower than
78% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 1.16 vs. DRAD: 1.68 )
Ranked among companies with meaningful Price/Median PS Value only.
DRAD' s 10-Year Price/Median PS Value Range
Min: 0.02  Med: 1.00 Max: 2.32
Current: 1.68
0.02
2.32
Price/Graham Number 1.75
DRAD's Price/Graham Number is ranked higher than
60% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. DRAD: 1.75 )
Ranked among companies with meaningful Price/Graham Number only.
DRAD' s 10-Year Price/Graham Number Range
Min: 1.31  Med: 1.86 Max: 10.23
Current: 1.75
1.31
10.23
Earnings Yield (Greenblatt) (%) 4.56
DRAD's Earnings Yield (Greenblatt) (%) is ranked higher than
75% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. DRAD: 4.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DRAD' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.3  Med: 4.80 Max: 475
Current: 4.56
0.3
475

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:FDV.Germany,
Digirad Corp was incorporated in Delaware in 1997. The Company is a developer and manufacturer of medical diagnostic imaging systems including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications. The business is organized into two reportable segments: Digirad Imaging Solutions (DIS) and Diagnostic Imaging. It is a provider of in-office nuclear cardiology imaging and ultrasound services to physician practices, hospitals and imaging centers through Digirad Imaging Solutions ("DIS") business segment. The Company sells medical diagnostic imaging systems including solid-state gamma cameras for nuclear cardiology and general nuclear medicine applications, as well as provides service on the products it sells through its Diagnostic Imaging segment. The target market for its products and services is comprised of cardiologists, internal medicine physicians, family practice physicians, and hospitals in the United States that perform or could perform nuclear and ultrasound diagnostic imaging procedures. The Company sells a line of nuclear imaging cameras for nuclear cardiology and general nuclear medicine applications. Its cameras are used in hospitals, imaging centers, physician offices and by mobile service providers. Its product Ergo large-field-of-view imaging system is targeted to hospitals with multi-camera general nuclear medicine departments, academic centers, pediatric hospitals, regional trauma centers, women's health centers, and cancer centers. Its Cardius XACT SPECT/CT system features a triple-head design and a low dose volume CT attenuation correction methodology, making it possible to perform studies faster with greater interpretation diagnostic confidence. It uses variety of materials, metals and mechanical and electrical components for production of its products. The Company maintain two sales organizations, which operate independently but in cooperation with each other: Diagnostic Imaging sales and DIS sales. The Company's operations comply with an array of federal and state laws and regulations.
» More Articles for DRAD

Headlines

Articles On GuruFocus.com
Top 3 Insider Buys Highlighted by Energy Companies Jul 12 2013 
DRAD Directors Increase Their Stake in the Medical Supply Company Apr 25 2013 
Expansion Initiates Insider Buying for NTS Apr 11 2013 
Digirad Corp. Reports Operating Results (10-K/A) Jul 30 2010 
Digirad Corp. Reports Operating Results (10-Q) Jul 29 2010 
Digirad Corp. Reports Operating Results (10-Q) Apr 29 2010 
Digirad Corporation Q3 2009 update Oct 29 2009 
Miguel Barbosa Interviews Famous Blogger, Greenbackd! Oct 29 2009 
Digirad Corp. Reports Operating Results (10-Q) Oct 22 2009 
Digirad Corporation Reports Fourth Quarter and Full Year 2008 Financial Results Feb 05 2009 

More From Other Websites
DIGIRAD CORP Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements... Jun 26 2015
DIGIRAD CORP Financials May 08 2015
DIGIRAD CORP Files SEC form 8-K, Material Modification to Rights of Security Holders May 05 2015
Digirad Corporation to Present at the B. Riley and Company 16th Annual Investor Conference on May... May 04 2015
Digirad Corporation to Present at the B. Riley and Company 16th Annual Investor Conference on May... May 04 2015
10-Q for Digirad Corp. May 03 2015
DIGIRAD CORP Files SEC form 10-Q, Quarterly Report May 01 2015
Digirad Corp Earnings Call scheduled for 11:00 am ET today Apr 30 2015
Q1 2015 Digirad Corp Earnings Release - Before Market Open Apr 30 2015
Digirad posts 1Q profit Apr 30 2015
Digirad posts 1Q profit Apr 30 2015
Digirad Corporation Reports Financial Results for First Quarter of 2015 Apr 30 2015
DIGIRAD CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Apr 30 2015
Digirad Corporation Reports Financial Results for First Quarter of 2015 Apr 30 2015
Buy These 11 Small-Cap Stocks for Their Solid Dividends Apr 28 2015
Digirad Corporation to Release 2015 First Quarter Financial Results on April 30, 2015 Apr 17 2015
Digirad Corporation to Release 2015 First Quarter Financial Results on April 30, 2015 Apr 17 2015
Digirad Corp Earnings Call scheduled for 11:00 am ET today Mar 06 2015
DIGIRAD CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Mar 06 2015
Digirad Corporation Acquires MD Office Solutions, Inc. Mar 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK